ArticleBiomolecules & biomedicine2026
Pretreatment and dynamic neutrophil-to-lymphocyte ratio in relation to CT-based volumetric response to platinum-based neoadjuvant chemotherapy in NSCLC.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neutrophil to lymphocyte ratio (NLR) serves as a marker of systemic inflammation and is an established prognostic factor in non-small cell lung cancer (NSCLC). However, its predictive value for treatment response, particularly when evaluated through three-dimensional CT volumetry, remains ambiguous. This study investigates whether pretreatment NLR and treatment-related changes in NLR correlate with volumetric tumor response to platinum-based neoadjuvant chemotherapy (NACT). Adult patients with histologically confirmed NSCLC who received platinum-based NACT and had evaluable pre- and posttreatment CT imaging were included in the analysis. Tumor response was defined as a ≥30% reduction using three-dimensional CT volumetry. We analyzed pretreatment NLR, posttreatment NLR, changes in NLR (ΔNLR), and the NLR ratio. To enhance statistical stability, additional analyses utilized log-transformed NLR values. Associations were examined through non-parametric tests, correlation analysis, and both univariable and multivariable logistic regression models adjusted for age, sex, histology, disease stage, performance status, and baseline tumor volume. A total of 70 patients were included, with 33 (47.1%) achieving a volumetric response. NLR decreased during treatment (median ΔNLR = -0.42), yet no significant differences were noted between responders and non-responders regarding pretreatment NLR (p = 0.773), posttreatment NLR (p = 0.920), ΔNLR (p = 0.514), or NLR ratio (p = 0.630). None of the NLR-derived parameters showed significant associations with treatment response in univariable or multivariable models, including those utilizing log-transformed variables. Furthermore, the NLR ratio exhibited substantial instability, reflected in wide confidence intervals. In conclusion, within this cohort, neither pretreatment nor dynamic NLR parameters were significantly associated with CT-based volumetric tumor response following platinum-based NACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.